CN115867346B - 激酶抑制剂 - Google Patents

激酶抑制剂 Download PDF

Info

Publication number
CN115867346B
CN115867346B CN202180048117.5A CN202180048117A CN115867346B CN 115867346 B CN115867346 B CN 115867346B CN 202180048117 A CN202180048117 A CN 202180048117A CN 115867346 B CN115867346 B CN 115867346B
Authority
CN
China
Prior art keywords
formula
mmol
methyl
indole
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180048117.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN115867346A (zh
Inventor
克雷格·艾伦·科伯恩
丹格·维杰·库马尔
丹尼尔·约翰·布扎德
尼迪·阿罗拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vitia Treatment Co ltd
Original Assignee
GB005 Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GB005 Inc filed Critical GB005 Inc
Publication of CN115867346A publication Critical patent/CN115867346A/zh
Application granted granted Critical
Publication of CN115867346B publication Critical patent/CN115867346B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202180048117.5A 2020-06-02 2021-06-02 激酶抑制剂 Active CN115867346B (zh)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US202063033729P 2020-06-02 2020-06-02
US202063033728P 2020-06-02 2020-06-02
US202063033724P 2020-06-02 2020-06-02
US63/033,724 2020-06-02
US63/033,728 2020-06-02
US63/033,729 2020-06-02
US202163136593P 2021-01-12 2021-01-12
US202163136587P 2021-01-12 2021-01-12
US202163136577P 2021-01-12 2021-01-12
US63/136,577 2021-01-12
US63/136,587 2021-01-12
US63/136,593 2021-01-12
PCT/US2021/035509 WO2021247748A1 (en) 2020-06-02 2021-06-02 Kinase inhibitors

Publications (2)

Publication Number Publication Date
CN115867346A CN115867346A (zh) 2023-03-28
CN115867346B true CN115867346B (zh) 2025-03-14

Family

ID=76601840

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180048117.5A Active CN115867346B (zh) 2020-06-02 2021-06-02 激酶抑制剂

Country Status (7)

Country Link
US (1) US12448363B2 (https=)
EP (1) EP4157446A1 (https=)
JP (2) JP2023528421A (https=)
CN (1) CN115867346B (https=)
AU (1) AU2021283916A1 (https=)
CA (1) CA3179637A1 (https=)
WO (1) WO2021247748A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021398051A1 (en) 2020-12-10 2023-07-27 Principia Biopharma Inc. Crystal form of tolebrutinib, preparation method therefor and use thereof
CN117915960A (zh) * 2021-08-30 2024-04-19 百时美施贵宝公司 可用于布鲁顿酪氨酸激酶的pet成像的化合物
WO2023227080A1 (zh) * 2022-05-25 2023-11-30 百极弘烨(南通)医药科技有限公司 一种protac化合物、含其的药物组合物及其制备方法和应用
JP2025521510A (ja) * 2022-06-22 2025-07-10 プリンシピア バイオファーマ インコーポレイテッド 改変されたｂｔｋ阻害剤の作製方法
CN116284025B (zh) * 2023-02-20 2025-07-04 国科大杭州高等研究院 一种具有抗癌作用的螺杂环类化合物、药物组合物及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107108583A (zh) * 2014-10-24 2017-08-29 百时美施贵宝公司 可用作激酶抑制剂的吲哚甲酰胺化合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6509838B2 (ja) * 2013-06-26 2019-05-08 アッヴィ・インコーポレイテッド Ｂｔｋ阻害薬としての一級カルボキサミド類
SI3209651T1 (sl) * 2014-10-24 2019-12-31 Bristol-Myers Squibb Company Derivati karbazola

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107108583A (zh) * 2014-10-24 2017-08-29 百时美施贵宝公司 可用作激酶抑制剂的吲哚甲酰胺化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton’s Tyrosine Kinase (BTK);Scott H. Watterson;Journal of Medicinal Chemistry;第62卷(第7期);3228-3250 *

Also Published As

Publication number Publication date
JP2023528421A (ja) 2023-07-04
EP4157446A1 (en) 2023-04-05
WO2021247748A1 (en) 2021-12-09
CA3179637A1 (en) 2021-12-09
US20230219923A1 (en) 2023-07-13
AU2021283916A1 (en) 2023-01-05
CN115867346A (zh) 2023-03-28
JP2026048716A (ja) 2026-03-17
US12448363B2 (en) 2025-10-21

Similar Documents

Publication Publication Date Title
CN112778276B (zh) 作为shp2抑制剂的化合物及其应用
CN115867346B (zh) 激酶抑制剂
TWI902789B (zh) 藉由軛合ｂｔｋ抑制劑與ｅ３連接酶配位基降解布魯頓氏酪胺酸激酶（ｂｔｋ）及其使用方法
WO2023061294A1 (zh) 含氮杂环类衍生物调节剂、其制备方法及应用
TWI592413B (zh) 作為ｊａｋ１抑制劑之哌啶-４-基三亞甲亞胺衍生物
CN113637005A (zh) 用于癌症治疗的kras抑制剂
TWI676622B (zh) 作為rho激酶抑制劑的異喹啉磺醯衍生物
WO2022143856A1 (en) Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use
EA036630B1 (ru) Бициклические производные
CN116783199A (zh) 作为btk抑制剂的吡唑并[1,5-a]吡嗪衍生物
JP2026508745A (ja) アミド又はウレア系化合物
TW202510858A (zh) 治療自體免疫疾病之大環
TW202334167A (zh) 作為ｅｒｂｂ２抑制劑之稠合四環喹唑啉衍生物
CN111655690B (zh) 吡唑并吡啶酮化合物
TW202327592A (zh) Cdk9抑制劑及其用途
CN110655520A (zh) 嘧啶并环化合物及其制备方法和应用
TW202448888A (zh) 三環雜環衍生物及其組合物和應用
CN114644631A (zh) Kras g12c蛋白突变抑制剂、其制备方法、药物组合物及其应用
EP4132910A1 (en) Kinase inhibitors
TW202517653A (zh) 治療自體免疫疾病之大環
AU2022209175A1 (en) Indole derivatives as kinase inhibitors
EP3028703B1 (en) Piperidine derivatives as wnt signaling inhibitor
JP2025514712A (ja) ブロモドメインに対して活性な化合物
TW202523301A (zh) Ripk1抑制劑及使用方法
TW202608884A (zh) 藉由軛合btk抑制劑與e3連接酶配位基降解布魯頓氏酪胺酸激酶（btk）及其使用方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20251011

Address after: California, USA

Patentee after: VITIA SUBSIDIARY Ltd.

Country or region after: U.S.A.

Address before: California, USA

Patentee before: GB005 Corp.

Country or region before: U.S.A.

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20251103

Address after: 378 Neptune Ave, Encinitas, CA, United States

Patentee after: Vitia Treatment Co.,Ltd.

Country or region after: U.S.A.

Address before: California, USA

Patentee before: VITIA SUBSIDIARY Ltd.

Country or region before: U.S.A.